RTW vs. WWH, JTC, FGT, PIN, ATT, BNKR, N91, VEIL, LWDB, and TFG
Should you be buying RTW Biotech Opportunities stock or one of its competitors? The main competitors of RTW Biotech Opportunities include Worldwide Healthcare (WWH), JTC (JTC), Finsbury Growth & Income (FGT), Pantheon International (PIN), Allianz Technology Trust (ATT), The Bankers Investment Trust (BNKR), Ninety One Group (N91), Vietnam Enterprise (VEIL), Law Debenture (LWDB), and Tetragon Financial (TFG). These companies are all part of the "asset management" industry.
RTW Biotech Opportunities vs.
Worldwide Healthcare (LON:WWH) and RTW Biotech Opportunities (LON:RTW) are both small-cap financial services companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, media sentiment, institutional ownership, community ranking and valuation.
Worldwide Healthcare received 71 more outperform votes than RTW Biotech Opportunities when rated by MarketBeat users. However, 100.00% of users gave RTW Biotech Opportunities an outperform vote while only 67.29% of users gave Worldwide Healthcare an outperform vote.
In the previous week, Worldwide Healthcare had 1 more articles in the media than RTW Biotech Opportunities. MarketBeat recorded 1 mentions for Worldwide Healthcare and 0 mentions for RTW Biotech Opportunities. Worldwide Healthcare's average media sentiment score of 1.81 beat RTW Biotech Opportunities' score of 0.00 indicating that Worldwide Healthcare is being referred to more favorably in the media.
Worldwide Healthcare has a beta of 0.29, indicating that its stock price is 71% less volatile than the S&P 500. Comparatively, RTW Biotech Opportunities has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500.
RTW Biotech Opportunities has a net margin of 664.38% compared to Worldwide Healthcare's net margin of 92.78%. RTW Biotech Opportunities' return on equity of 25.18% beat Worldwide Healthcare's return on equity.
73.6% of Worldwide Healthcare shares are owned by institutional investors. Comparatively, 3.9% of RTW Biotech Opportunities shares are owned by institutional investors. 0.4% of Worldwide Healthcare shares are owned by company insiders. Comparatively, 16.2% of RTW Biotech Opportunities shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
RTW Biotech Opportunities has higher revenue and earnings than Worldwide Healthcare. RTW Biotech Opportunities is trading at a lower price-to-earnings ratio than Worldwide Healthcare, indicating that it is currently the more affordable of the two stocks.
Summary
RTW Biotech Opportunities beats Worldwide Healthcare on 8 of the 15 factors compared between the two stocks.
Get RTW Biotech Opportunities News Delivered to You Automatically
Sign up to receive the latest news and ratings for RTW and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
RTW Biotech Opportunities Competitors List
Related Companies and Tools
This page (LON:RTW) was last updated on 4/25/2025 by MarketBeat.com Staff
Buy RTW Stock Free RTW Stock Alerts